Trial intelligence / Profile preview

BEGIN SIMPLIFY: Insulin Glargine to Insulin Degludec Switch in T2DM

NCT01135992Phase 3Completed

Sponsor
Novo Nordisk
Start
Jun 2010
Primary completion
Nov 2010
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jun 2010; status: completed.

02

Drugs

insulin degludec
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT01135992.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01135992.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call